Ann Rheum Dis: Human umbilical cord-to-cord hyperplial stem cell transplant combined with IFN-sic can work together to improve clinical outcomes of rheumatoid arthritis
-
Last Update: 2020-07-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The study aims to clarify the key role of cyclic interferon-rhodium (IFN-cynto) in patients withrheumatoid arthritis (RA) and to improve the clinical efficacy of interstitialstem cell(MSCT)first evaluated wild type or IFN-R-/-MSCT in the collagen-induced arthritis (CIA) mouse model, followed by a 1/2 randomized controlled study of 63 RA patients who were not effective with conventional treatmentThe subjects were randomly divided into MSCT individual treatment group (n-32) or MSCT co-recombinant IFN-sic treatment group (n-31) and followed up for 1 yearThe main endpoints included a positive or moderate EULAR response rate, and a percentage of patients who met the American Society of Rheumatology 20 (ACR20) response rate at 3 monthsin mouse models, wild-type MSCT significantly improves the clinical severity of the CIA, while IFN-R-/-MSCT aggravates glioscosis and joint and cartilage damageThe three-month follow-up results from mouse studies to clinical studies showed that 53.3% of MSCT patients were treated separately and 93.3% of MSCT combined IFN-spused patients achieved efficacy and ACR20 response rate (p0.05)Neither treatment group experienced new or unexpected safety problems during the one-year follow-upthe results show that IFN-stomp is a key factor in determining the efficacy of MSCT on RA, and that MSC's combined IFN-stomp treatment strategy can greatly improve the clinical efficacy of MSC on RA
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
